ATAI AtaiBeckley Inc.
ATAI AtaiBeckley Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-11 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Reported EPS $-0.09 versus analyst consensus of $-0.11 (+19.4%).
full note →Against street estimates
How ATAI's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about ATAI from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 36 days ago · Sep 11
- AtaiBeckley sale to Lilly pays $6.75 plus CVR | ATAI 8-K Filing
- AtaiBeckley Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | MarketScreener
- ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com
- AtaiBeckley (NASDAQ: ATAI) to be acquired by Eli Lilly in $6.75 cash deal plus CVR
- ATAI Stock Soars As Eli Lilly Takeover Talks Heat Up
ATAI research tape
44 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.